Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 176

The DOI matches its Crossref record.

RESULTS OF DIFFERENT STRATEGIES FOR REDUCING CYTOMEGALOVIRUS-ASSOCIATED MORTALITY IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS1

Ljungman, Per, Aschan, Johan, Lewensohn-Fuchs, Ilona, Carlens, Stefan, Larsson, Kajsa, L??nnqvist, Berit, Mattsson, Jonas, Sparrelid, Elda, Winiarski, Jacek, Ringd??n, Olle · 1998 · Transplantation

Abstract

BACKGROUND: Several preventive strategies against cytomegalovirus (CMV) disease have been developed during the last decade. These have frequently been used in combination, and it has been difficult to identify each strategy's contribution. METHODS: Risk factors for CMV disease, death in CMV disease and transplant-related mortality were analyzed in 584 patients, who underwent a total of 594 allogeneic bone marrow transplants. RESULTS: The overall probability of CMV disease was 8.9%. No seronegative patient who had a seronegative marrow donor developed CMV disease. The corresponding probabilities for seronegative patients with seropositive donors, seropositive patients with seronegative donors, and seropositive patients with seropositive donors were 5.4%, 13.7%, and 11.7%, respectively. In multivariate Cox models, the use of preemptive antiviral therapy and being CMV-seronegative reduced the risk for CMV disease, CMV-associated death, and transplant-related mortality (TRM). Patients who received unrelated or mismatched family donor transplants had increased risks for CMV disease, CMV-associated death, and TRM. Older age was a significant risk factor for CMV disease and TRM. A total of 258 patients who were monitored by polymerase chain reaction for CMV DNA were analyzed separately to assess whether addition of another CMV preventive strategy could give benefit. Patients who received mismatched or unrelated donor transplants had increased risk for CMV disease, death in CMV disease, and TRM. High-dose acyclovir prophylaxis or addition of intravenous immune globulin had no influence. CONCLUSIONS: Preemptive therapy based on polymerase chain reaction for CMV DNA was associated with reduced risks for CMV disease, CMV-associated death, and TRM, whereas other prophylactic modalities did not give additional benefit.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00007890-199811270-00012

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 176

Metadata

Authors
Ljungman, P., Aschan, J., Lewensohn-Fuchs, I., Carlens, S., Larsson, K., L??nnqvist, B., Mattsson, J., Sparrelid, E., Winiarski, J., & Ringd??n, O.
Venue
Transplantation
Published
1998-11
Volume
66
Issue
10
Pages
1330-1334
ISSN
0041-1337 (ISSN-L)
OpenAlex
W2136497987
Cited by
176
References
0
FWCI
4.08
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: RESULTS OF DIFFERENT STRATEGIES FOR REDUCING CYTOMEGALOVIRUS-ASSOCIATED MORTALITY IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS1. https://app.cochat.ai/papers/10.1097/00007890-199811270-00012
The paper
Ljungman, P., Aschan, J., Lewensohn-Fuchs, I., Carlens, S., Larsson, K., L??nnqvist, B., Mattsson, J., Sparrelid, E., Winiarski, J., & Ringd??n, O. (1998). RESULTS OF DIFFERENT STRATEGIES FOR REDUCING CYTOMEGALOVIRUS-ASSOCIATED MORTALITY IN ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS1. Transplantation. https://doi.org/10.1097/00007890-199811270-00012

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.